Pharmaceutical

CTX-310 by CRISPR Therapeutics for Heterozygous familial hypercholesterolemia (heFH): Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH).

Jul 6, 2024 - 04:00
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH).
Read the original article

Tags:

Previous Article

NN-6561 by Novo Nordisk for Metabolic Dysfunction-Associated Steatohepatitis (MA...

Next Article

CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoF...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Ocular Therapeutix gets grant for intracanalicular inje...

Aug 23, 2024

Michael J. Fox on how far Parkinson’s research has come: ‘We don’t want to be celebrated. We want to get things done’

Michael J. Fox on how far Parkinson’s research has come...

Oct 20, 2023

STAT+: Democrats already want to expand Medicare drug price negotiation

STAT+: Democrats already want to expand Medicare drug p...

Jul 26, 2023